Interaction among Toll-like receptors and other pattern recognition receptors in innate immune

XU Jing; DING Li; ZHANG Junping

doi:10.3969/j.issn.1006-0111.2014.05.002

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 32 Issue 5

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2014 > 32(5): 324-328,400

XU Jing, DING Li, ZHANG Junping. Interaction among Toll-like receptors and other pattern recognition receptors in innate immune[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(5): 324-328,400. doi: 10.3969/j.issn.1006-0111.2014.05.002

Citation:

XU Jing, DING Li, ZHANG Junping. Interaction among Toll-like receptors and other pattern recognition receptors in innate immune[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(5): 324-328,400. doi: 10.3969/j.issn.1006-0111.2014.05.002

Interaction among Toll-like receptors and other pattern recognition receptors in innate immune

doi: 10.3969/j.issn.1006-0111.2014.05.002

Department of Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2013-04-14
Rev Recd Date: 2014-03-21

Abstract

Toll-like receptors (TLRs) are germline-encoded pattern recognition receptors (PRRs) that play a central role in host cell recognition and responses to microbial pathogens. TLRs-mediated recognition of components derived from a wide range of pathogens and their role in the subsequent initiation of innate immune responses is widely accepted, besides, the recent discovery of non-TLR PRRs, such as C-type lectin receptors, NOD-like receptors, and RIG-I-like receptors, suggests that many aspects of innate immunity are more sophisticated and complicated. In this review, we focused on the role cooperated by TLRs in mounting protective immune responses against infection and their crosstalk with other PRRs with respect to pathogen recognition.
- Toll-like receptors (TLRs),
- pattern recognition receptors,
- innate immune

References

[1]	Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity[J].Cell, 2006, 124(4):783-802.
[2]	Kawai T,Akira S. The role of pattern-recognition receptors in innate immunity:update on Toll-like receptors[J].Nat Immunol, 2010, 11(5):373-384.
[3]	Elinav E, Strowig T, Henao-Mejia J. Regulation of the antimicrobial response by NLR proteins[J].Immunity,2011, 34(5):665-679.
[4]	Loo YM,Gale M. Immune signaling by RIG-I-like receptors[J].Immunity, 2011, 34(5):680-692.
[5]	Osorio F,Reis-e-Sousa C. Myeloid C-type lectin receptors in pathogen recognition and host defense[J].Immunity, 2011, 34(5):651-664.
[6]	Adachi K, Tsutsui H, Kashiwamura S. Plasmodium berghei infection in mice induces liver injury by an IL-12-and Toll-like receptor/myeloid differentiation factor 88-dependent mechanism[J].J Immunol, 2001, 167(10):5928-5934.
[7]	Beutler BA. TLRs and innate immunity[J].Blood, 2009, 113(7):1399-1407.
[8]	Blasius AL,Beutler B. Intracellular toll-like receptors[J].Immunity, 2010, 32(3):305-315.
[9]	Pifer R, Benson A, Sturge CR. UNC93B1 is essential for TLR11 activation and IL-12-dependent host resistance to Toxoplasma gondii[J].J Bio Chem, 2011, 286(5):3307-3314.
[10]	Kobayashi K, Hernandez LD, Galan JE. IRAK-M is a negative regulator of Toll-like receptor signaling[J].Cell, 2002,110(2):191-202.
[11]	Barton GM,Kagan JC. A cell biological view of Toll-like receptor function:regulation through compartmentalization[J].Nat Rev Immunol, 2009, 9(8):535-542.
[12]	Sasai M, Linehan MM, Iwasaki A. Bifurcation of Toll-like receptor 9 signaling by adaptor protein 3[J].Science, 2010, 329(5998):1530-1534.
[13]	Haas T, Metzger J, Schmitz F. The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation[J].Immunity, 2008, 28(3):315-323.
[14]	Park B, Buti L, Matsuwaki T. Granulin is a soluble cofactor for toll-like receptor 9 signaling[J].Immunity, 2011, 34(4):505-513.
[15]	Mancuso G, Gambuzza M, Midiri A. Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells[J].Nat immunol, 2009, 10(6):587-594.
[16]	Miao EA, Andersen-Nissen E, Warren SE. TLR5 and Ipaf:dual sensors of bacterial flagellin in the innate immune system[J].Semin Immunopathol, 2007, 29(3):275-288.
[17]	Gerold G, Zychlinsky A,de Diego JL. What is the role of Toll-like receptors in bacterial infections[J].Semin Immunol, 2007, 19(1):41-47.
[18]	Weiss DS, Raupach B, Takeda K. Toll-like receptors are temporally involved in host defense[J].J Immunol,2004, 172(7):4463-4469.
[19]	Feuillet V, Medjane S, Mondor I. Involvement of Toll-like receptor 5 in the recognition of flagellated bacteria[J].Proc Natl Acad of Sci, 2006, 103(33):12487-12492.
[20]	Saiga H, Shimada Y, Takeda K. Innate immune effectors in mycobacterial infection[J].Clin Develop Immunol, 2011, 2011:347594.
[21]	H lscher C, Reiling N, Schaible UE. Containment of aerogenic Mycobacterium tuberculosis infection in mice does not require MyD88 adaptor function for TLR2,4 and9 [J].Eur J Immunol,2008, 38(3):680-694.
[22]	Gandotra S, Jang S, Murray PJ. Nucleotide-binding oligomerization domain protein 2-deficient mice control infection with Mycobacterium tuberculosis[J].Infect Immun,2007, 75(11):5127-5134.
[23]	Dorhoi A, Desel C, Yeremeev V. The adaptor molecule CARD9 is essential for tuberculosis control[J].J Exp Med, 2010, 207(4):777-792.
[24]	Reizis B, Bunin A, Ghosh HS. Plasmacytoid dendritic cells:recent progress and open questions[J].Annu Rev Immunol, 2011, 29:163-183.
[25]	Lee HK, Lund JM, Ramanathan B. Autophagy-dependent viral recognition by plasmacytoid dendritic cells[J].Science,2007, 315(5817):1398-1401.
[26]	Kumagai Y, Takeuchi O, Kato H. Alveolar macrophages are the primary interferon-α producer in pulmonary infection with RNA viruses[J].Immunity, 2007, 27(2):240-252.
[27]	Lemon SM. Induction and evasion of innate antiviral responses by hepatitis C virus[J].J Biol Chem, 2010, 285(30):22741-22747.
[28]	Shiina M, Rehermann B. Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function[J].Hepatology,2008, 47(2):385-395.
[29]	Jasani B, Navabi H, Adams M. Ampligen:a potential toll-like 3 receptor adjuvant for immunotherapy of cancer[J].Vaccine, 2009, 27(25):3401-3404.
[30]	Navabi H, Jassni B, Reece A. A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro[J].Vaccine, 2009, 27(1):107-115.
[31]	Krieg AM. Toll-free vaccines[J].Nat Biotechnol, 2007, 25(3):303-305.
[32]	Huleatt JW, Nakaar V, Desai P. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin[J].Vaccine,2008, 26(2):201-214.
[33]	Kronenberger B,Zeuzem S. Current and future treatment options for HCV[J].Ann Hepatol,2009, 8(2):103-112.
[34]	Agrawal S,Kandimalla ER. Synthetic agonists of Toll-like receptors 7, 8 and 9[J].Biochem Soc Trans, 2007, 35(Pt 6):1461-1467.
[35]	Barry M, Cooper C. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy[J].Expert Opin Biol Ther, 2007, 7(11):1731-1737.
[36]	Rice TW, Wheeler AP, Bernard GR. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis[J].Crit Care Med, 2010, 38(8):1685-1694.
[37]	Ledeboer A, Liu T, Shumilla JA. The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain[J].Neuron Glia Biol, 2006, 2(4):279-291.
[38]	Ledeboer A, Hutchinson MR, Watkins LR. Ibudilast (AV-411) a new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes[J].Expert Opin Invest Drugs, 2007, 16(7):935-950.
[39]	Urbonaviciute V, Furnrohr,BF, Meister S. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes:implications for the pathogenesis of SLE[J].J Exp Med, 2008, 205(13):3007-3018.
[40]	Arslan F, de Kleijn DP, Timmers L. Bridging innate immunity and myocardial ischemia/reperfusion injury:the search for therapeutic targets[J].Curr Pharm Des, 2008, 14(12):1205-1216.
[41]	Sun S, Rao NL, Venable J. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders[J]. Inflamm Allergy Drug Targets, 2007, 6(4):223-235.
[42]	Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors:emerging therapeutics[J].Nat Rev Drug Discov, 2010, 9(4):293-307.

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(4546) PDF downloads(257) Cited by()

Proportional views

Interaction among Toll-like receptors and other pattern recognition receptors in innate immune

Department of Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2013-04-14

Rev Recd Date: 2014-03-21

Key words:

Abstract: Toll-like receptors (TLRs) are germline-encoded pattern recognition receptors (PRRs) that play a central role in host cell recognition and responses to microbial pathogens. TLRs-mediated recognition of components derived from a wide range of pathogens and their role in the subsequent initiation of innate immune responses is widely accepted, besides, the recent discovery of non-TLR PRRs, such as C-type lectin receptors, NOD-like receptors, and RIG-I-like receptors, suggests that many aspects of innate immunity are more sophisticated and complicated. In this review, we focused on the role cooperated by TLRs in mounting protective immune responses against infection and their crosstalk with other PRRs with respect to pathogen recognition.

HTML

Reference (42)

[1]	Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity[J].Cell, 2006, 124(4):783-802.
[2]	Kawai T,Akira S. The role of pattern-recognition receptors in innate immunity:update on Toll-like receptors[J].Nat Immunol, 2010, 11(5):373-384.
[3]	Elinav E, Strowig T, Henao-Mejia J. Regulation of the antimicrobial response by NLR proteins[J].Immunity,2011, 34(5):665-679.
[4]	Loo YM,Gale M. Immune signaling by RIG-I-like receptors[J].Immunity, 2011, 34(5):680-692.
[5]	Osorio F,Reis-e-Sousa C. Myeloid C-type lectin receptors in pathogen recognition and host defense[J].Immunity, 2011, 34(5):651-664.
[6]	Adachi K, Tsutsui H, Kashiwamura S. Plasmodium berghei infection in mice induces liver injury by an IL-12-and Toll-like receptor/myeloid differentiation factor 88-dependent mechanism[J].J Immunol, 2001, 167(10):5928-5934.
[7]	Beutler BA. TLRs and innate immunity[J].Blood, 2009, 113(7):1399-1407.
[8]	Blasius AL,Beutler B. Intracellular toll-like receptors[J].Immunity, 2010, 32(3):305-315.
[9]	Pifer R, Benson A, Sturge CR. UNC93B1 is essential for TLR11 activation and IL-12-dependent host resistance to Toxoplasma gondii[J].J Bio Chem, 2011, 286(5):3307-3314.
[10]	Kobayashi K, Hernandez LD, Galan JE. IRAK-M is a negative regulator of Toll-like receptor signaling[J].Cell, 2002,110(2):191-202.
[11]	Barton GM,Kagan JC. A cell biological view of Toll-like receptor function:regulation through compartmentalization[J].Nat Rev Immunol, 2009, 9(8):535-542.
[12]	Sasai M, Linehan MM, Iwasaki A. Bifurcation of Toll-like receptor 9 signaling by adaptor protein 3[J].Science, 2010, 329(5998):1530-1534.
[13]	Haas T, Metzger J, Schmitz F. The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation[J].Immunity, 2008, 28(3):315-323.
[14]	Park B, Buti L, Matsuwaki T. Granulin is a soluble cofactor for toll-like receptor 9 signaling[J].Immunity, 2011, 34(4):505-513.
[15]	Mancuso G, Gambuzza M, Midiri A. Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells[J].Nat immunol, 2009, 10(6):587-594.
[16]	Miao EA, Andersen-Nissen E, Warren SE. TLR5 and Ipaf:dual sensors of bacterial flagellin in the innate immune system[J].Semin Immunopathol, 2007, 29(3):275-288.
[17]	Gerold G, Zychlinsky A,de Diego JL. What is the role of Toll-like receptors in bacterial infections[J].Semin Immunol, 2007, 19(1):41-47.
[18]	Weiss DS, Raupach B, Takeda K. Toll-like receptors are temporally involved in host defense[J].J Immunol,2004, 172(7):4463-4469.
[19]	Feuillet V, Medjane S, Mondor I. Involvement of Toll-like receptor 5 in the recognition of flagellated bacteria[J].Proc Natl Acad of Sci, 2006, 103(33):12487-12492.
[20]	Saiga H, Shimada Y, Takeda K. Innate immune effectors in mycobacterial infection[J].Clin Develop Immunol, 2011, 2011:347594.
[21]	H lscher C, Reiling N, Schaible UE. Containment of aerogenic Mycobacterium tuberculosis infection in mice does not require MyD88 adaptor function for TLR2,4 and9 [J].Eur J Immunol,2008, 38(3):680-694.
[22]	Gandotra S, Jang S, Murray PJ. Nucleotide-binding oligomerization domain protein 2-deficient mice control infection with Mycobacterium tuberculosis[J].Infect Immun,2007, 75(11):5127-5134.
[23]	Dorhoi A, Desel C, Yeremeev V. The adaptor molecule CARD9 is essential for tuberculosis control[J].J Exp Med, 2010, 207(4):777-792.
[24]	Reizis B, Bunin A, Ghosh HS. Plasmacytoid dendritic cells:recent progress and open questions[J].Annu Rev Immunol, 2011, 29:163-183.
[25]	Lee HK, Lund JM, Ramanathan B. Autophagy-dependent viral recognition by plasmacytoid dendritic cells[J].Science,2007, 315(5817):1398-1401.
[26]	Kumagai Y, Takeuchi O, Kato H. Alveolar macrophages are the primary interferon-α producer in pulmonary infection with RNA viruses[J].Immunity, 2007, 27(2):240-252.
[27]	Lemon SM. Induction and evasion of innate antiviral responses by hepatitis C virus[J].J Biol Chem, 2010, 285(30):22741-22747.
[28]	Shiina M, Rehermann B. Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function[J].Hepatology,2008, 47(2):385-395.
[29]	Jasani B, Navabi H, Adams M. Ampligen:a potential toll-like 3 receptor adjuvant for immunotherapy of cancer[J].Vaccine, 2009, 27(25):3401-3404.
[30]	Navabi H, Jassni B, Reece A. A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro[J].Vaccine, 2009, 27(1):107-115.
[31]	Krieg AM. Toll-free vaccines[J].Nat Biotechnol, 2007, 25(3):303-305.
[32]	Huleatt JW, Nakaar V, Desai P. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin[J].Vaccine,2008, 26(2):201-214.
[33]	Kronenberger B,Zeuzem S. Current and future treatment options for HCV[J].Ann Hepatol,2009, 8(2):103-112.
[34]	Agrawal S,Kandimalla ER. Synthetic agonists of Toll-like receptors 7, 8 and 9[J].Biochem Soc Trans, 2007, 35(Pt 6):1461-1467.
[35]	Barry M, Cooper C. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy[J].Expert Opin Biol Ther, 2007, 7(11):1731-1737.
[36]	Rice TW, Wheeler AP, Bernard GR. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis[J].Crit Care Med, 2010, 38(8):1685-1694.
[37]	Ledeboer A, Liu T, Shumilla JA. The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain[J].Neuron Glia Biol, 2006, 2(4):279-291.
[38]	Ledeboer A, Hutchinson MR, Watkins LR. Ibudilast (AV-411) a new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes[J].Expert Opin Invest Drugs, 2007, 16(7):935-950.
[39]	Urbonaviciute V, Furnrohr,BF, Meister S. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes:implications for the pathogenesis of SLE[J].J Exp Med, 2008, 205(13):3007-3018.
[40]	Arslan F, de Kleijn DP, Timmers L. Bridging innate immunity and myocardial ischemia/reperfusion injury:the search for therapeutic targets[J].Curr Pharm Des, 2008, 14(12):1205-1216.
[41]	Sun S, Rao NL, Venable J. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders[J]. Inflamm Allergy Drug Targets, 2007, 6(4):223-235.
[42]	Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors:emerging therapeutics[J].Nat Rev Drug Discov, 2010, 9(4):293-307.

Message Board

Interaction among Toll-like receptors and other pattern recognition receptors in innate immune

doi: 10.3969/j.issn.1006-0111.2014.05.002

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views